| 10.165 0.165 (1.65%) | 06-15 13:29 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.23 |
1-year : | 15.45 |
| Resists | First : | 11.32 |
Second : | 13.23 |
| Pivot price | 10.58  |
|||
| Supports | First : | 9.89 |
Second : | 9.01 |
| MAs | MA(5) : | 10.14 |
MA(20) : | 10.58 |
| MA(100) : | 10.72 |
MA(250) : | 41.24 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 25.9 |
D(3) : | 26.4 |
| RSI | RSI(14): 45.3 |
|||
| 52-week | High : | 196.69 | Low : | 8.67 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NVNO ] has closed above bottom band by 29.5%. Bollinger Bands are 37.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.44 - 10.5 | 10.5 - 10.55 |
| Low: | 9.58 - 9.66 | 9.66 - 9.71 |
| Close: | 9.9 - 10.01 | 10.01 - 10.09 |
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
Fri, 12 Jun 2026
Insider Selling: Francis Duhay Sells Shares of enVVeno Medical C - GuruFocus
Fri, 12 Jun 2026
Director at enVVeno Medical (NASDAQ: NVNO) sells 140 shares under Rule 10b5-1 plan - Stock Titan
Thu, 11 Jun 2026
[144] enVVeno Medical Corp SEC Filing - Stock Titan
Thu, 04 Jun 2026
enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System - PhillyBurbs
Tue, 02 Jun 2026
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series - Yahoo Finance
Wed, 29 Apr 2026
enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve - ACCESS Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 1 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 13.3 (%) |
| Held by Institutions | 25.6 (%) |
| Shares Short | 70 (K) |
| Shares Short P.Month | 60 (K) |
| EPS | -31.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 36.2 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -37.6 % |
| Return on Equity (ttm) | -60.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -29.78 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.33 |
| PEG Ratio | 0 |
| Price to Book value | 0.28 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.47 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|